SCHEMBL3404564

SCHEMBL3404564

COc1ccc(-c2nc(C)c(C(=O)N3CCN(C(C)C)CC3)s2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.52
CNR1 P21554 1/20 0.47
TLR9 Q9NR96 1/20 0.47
TLR8 Q9NR97 1/20 0.47
TLR7 Q9NYK1 1/20 0.47
HPGD P15428 3/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
THRA P10827 2/20 0.45
THRB P10828 2/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
XDH P47989 2/20 0.43
MAPT P10636 3/20 0.43
HTR2C P28335 1/20 0.42
SCD5 Q86SK9 1/20 0.42
GAA P10253 1/20 0.42
TGFBR1 P36897 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404859 0.93 CNR1 (0.47) CFTRCNR1TLR9TLR8TLR7
SCHEMBL3402351 0.91 CNR1 (0.45) CFTRCNR1TLR9TLR8TLR7
SCHEMBL3402221 0.88 CNR1 (0.46) CFTRCNR1LMNAALDH1A1THRA
SCHEMBL3402114 0.88 CNR1 (0.47) CNR1HPGDKDM4EALDH1A1TSHR
SCHEMBL3405357 0.87 CNR1 (0.54) CNR1HPGDLMNAKDM4EALDH1A1
SCHEMBL3401619 0.86 CNR1 (0.53) CNR1HPGDLMNAKDM4EALDH1A1
SCHEMBL3402546 0.85 CNR1 (0.53) CNR1HPGDLMNAALDH1A1TSHR
SCHEMBL3405916 0.85 CNR1 (0.51) CNR1KDM4ETHRATHRBNPC1
SCHEMBL3402439 0.84 HTR2C (0.46) CFTRCNR1LMNAKDM4EALDH1A1
SCHEMBL3405399 0.83 CNR1 (0.57) CNR1KDM4EALDH1A1THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CFTR 3942/4885CNR1 35/4885TLR9 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.